CN107684567A - It is a kind of to be used to improve composite probiotics preparations that are fat and reducing blood fat - Google Patents
It is a kind of to be used to improve composite probiotics preparations that are fat and reducing blood fat Download PDFInfo
- Publication number
- CN107684567A CN107684567A CN201711081761.4A CN201711081761A CN107684567A CN 107684567 A CN107684567 A CN 107684567A CN 201711081761 A CN201711081761 A CN 201711081761A CN 107684567 A CN107684567 A CN 107684567A
- Authority
- CN
- China
- Prior art keywords
- fat
- group
- mouse
- composite probiotics
- sub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
It is used to improve composite probiotics preparations that are fat and reducing blood fat the invention discloses a kind of, is that bifidobacterium breve (Bifidobacterium breve) is mixed by following probiotics in proportion：Lactobacillus acidophilus (Lactobacillus acidophilus)：Lactobacillus casei (Lactobacillus casei)：The active bacteria number ratio of streptococcus thermophilus (Sterptococcus Thermophilus) is 0.5 1.5：0.5‑1.5：0.5‑1.5：0.5‑1.5；The total number of viable of composite probiotics preparations is at least 2,000,000,000/mL, the composite probiotics preparations can give obese mother in the gestational period and nursing period and take, to improve filial generation Flora Disturbance and blood lipid level, its effect of flora and blood fat and improving to filial generation can continue until the manhood.
Description
Technical field
It is particularly a kind of to be used to improve compound benefit that is fat and reducing blood fat the present invention relates to a kind of composite probiotics preparations
Probiotics preparation.
Background technology
Gravidic obesity is to influence the public health problem of baby's health.Gravidic obesity causes the concurrent of perinatal period
The incidence of disease rise of disease such as hypertension, high fat of blood, hyperglycaemia etc.；The obesity of mother is to cause fat speciality to be passed between generation-inter- simultaneously
The key factor passed.The obesity of gestational period mother is also the optimum prediction index for predicting that filial generation is fat.And of obesity in childhood
Body is easier to develop into the obesity of manhood, influences the general level of the health in long term.Therefore, overweight and fat pregnant woman not only influences certainly
The health of body forms remote effect to the health of filial generation simultaneously.Have very much for fat improvement means in world wide at present
Limit.
The organ that gut flora passes into silence as human body, participate in the normal physiology work(such as the immune of body, metabolism, development
Energy.Turn into the focus of international research with fat relation on gut flora in recent years.Especially Firmicutes and Bacteroidetes
Ratio change be probably the fat initiating occurred and lasting factor.Its unbalance, Obesity Pregnant Women that gut flora be present of Obesity Pregnant Women
, there is fat ratio rise in institute's produce surviving of son generation, lacks the effective means that cut-out obese mother antithetical phrase thanks to adverse effect from generation to generation at present.
The content of the invention
The present invention proposes a kind of composite probiotics preparations that can be effectively improved obesity and reduce blood fat.
The present invention technical solution be：A kind of composite probiotics preparations for being used to improve constipation, it is characterised in that：Institute
The composite probiotics preparations stated are mixed by following probiotics according to certain number of viable：Bifidobacterium breve
(Bifidobacterium breve)：Lactobacillus acidophilus (Lactobacillus acidophilus)：Lactobacillus casei
(Lactobacillus casei)：The ratio of streptococcus thermophilus (Sterptococcus Thermophilus) is 0.5-1.5：
0.5-1.5：0.5-1.5：0.5-1.5；The ratio being more highly preferred to is 0.5-1：0.5-1：0.5-1：0.5-1；Preferably ratio is
1：1：1：1, and the total number of viable of mixed composite probiotics preparations is at least 2,000,000,000/mL, is used to move with such a ratio
Thing is tested.This is a kind of composite probiotics preparations that can improve obesity and reduce blood fat.
Bifidobacterium breve (Bifidobacterium breve) described above, lactobacillus acidophilus (Lactobacillus
Acidophilus), Lactobacillus casei (Lactobacillus casei), streptococcus thermophilus (Sterptococcus
Thermophilus) strain can be bought from existing strain library and obtain, and strain number is as follows：Bifidobacterium breve
(Bifidobacterium breve)15700TM*, lactobacillus acidophilus (Lactobacillus acidophilus)314TM, Lactobacillus casei (Lactobacillus casei)393TM*, streptococcus thermophilus
(Sterptococcus Thermophilus)19258TM。
The present invention mainly carries out organic assembling using existing probiotics, and its composite bacteria agent gives fat parent in gestation
Phase, nursing period application, research show it to fat parent and filial generation Flora Disturbance, the improvement result of metabolism disorder of blood lipid, and its
Flora and blood fat and improving effect to filial generation can continue until the manhood.
Brief description of the drawings
The change curve of Fig. 1 mice weights：Control is control group dams, and HFD is high fat diet fat group dams,
Probiotics is that compound probiotic intervenes high fat diet group dams.
The change curve of Fig. 2 mouse body weight：Control is the sub- mouse of control group, and HFD is the sub- mouse of high fat diet fat group,
Probiotics is the sub- mouse of compound probiotic intervention group.
Fig. 3 dams flora 16Sr DNA sequencing results.M-C is control group dams, and M-HFD is fat group dams, and M-P is multiple
Close probiotics intervention group dams.
Fig. 4 mouse flora 16Sr DNA sequencing results.WF-C is Normal group female weaning stage sub- mouse, and WF-HFD is fertilizer
Fat group of female weaning stage sub- mouse, WF-P are compound probiotic intervention group female weaning stage sub- mouse, and WM-C is Normal group male
Weaning stage sub- mouse, WM-HFD are fat group male weaning stage sub- mouse, and WM-P is compound probiotic intervention group male weaning stage sub- mouse；
AF-C is Normal group female adult phase sub- mouse, and AF-HFD is fat group female adult phase sub- mouse, and AF-P is compound probiotic
Intervention group female adult phase sub- mouse, AM-C are Normal group male adult phase sub- mouse, and AM-HFD is the fat group male adult phase
Sub- mouse, AM-P are compound probiotic intervention group male adult phase sub- mouse.
Embodiment
Following non-limiting examples can make one of ordinary skill in the art be more fully understood the present invention, but not with
Any mode limits the present invention.
Embodiment 1
Research to Obesity in pregnant stage animal model
Take above-mentioned bifidobacterium breve (Bifidobacterium breve), lactobacillus acidophilus (Lactobacillus
Acidophilus), Lactobacillus casei (Lactobacillus casei), streptococcus thermophilus (Sterptococcus
Thermophilus) cultivate respectively, normal saline is used into plastc ring after collecting thalline.From SPF levels C57BL/
6J rats are randomly divided into 3 groups, respectively blank control group, obese model group, probiotics intervention group, give standard feed respectively
(70% carbohydrate, 20% protein, 10% fat), high lipid food (35% carbohydrate, 20% protein, 45%
Fat), high lipid food give probiotics (2,000,000,000) gavage daily simultaneously, male and female mate after raising 6 weeks, 6 weeks, the gestational period and lactation
Phase is respectively 21 days, after sub- mouse breast-feeding 21 days, all gives standard feed.Detect dams gestation the 1st day, sub- mouse 21 days and
The change of 42 days floras, analyze dams and the body weight and Blood Lipid of sub- mouse.
Each group mouse weight situation of change
See Fig. 1, the result of mice weight shows the body weight of obese model group dams apparently higher than control group, compound probiotic
Mixture intervention group mice weight is significantly lower than obese model group.The result of sub- mouse body weight is shown in Fig. 2, and the sub- mouse body weight of fat group is substantially high
In control group, the sub- mouse body weight of compound probiotic mixture intervention group is significantly lower than the sub- mouse body weight of fat group.
The change of each group mouse intestinal flora
Be shown in Table 1, the result of dams gestation gut flora change in the 1st day is shown, high fat diet cause dams gut flora α-
Chao1 and Shannon indexes in diversity are higher than normal group, and the intervention of compound probiotic mixture can reduce high fat diet induction
Dams gut flora α-diversity.
Table 1
| Groups | Chao1 | Ace | Shannon indices | Simpson indices |
| M-C | 788.1±40.9 | 780.2±39.8 | 5.4±0.29 | 0.91±0.02 |
| M-HFD | 821.3±25.1* | 796.9±24.5 | 6.2±0.21* | 0.95±0.02* |
| M-P | 689.6±30.7# | 682.6±28.1# | 5.2±0.31# | 0.92±0.01# |
| WF-C | 732.4±14.3 | 874.8±50.8 | 6.36±0.097 | 0.97±0.005 |
| WF-HFD | 593.2±114.6* | 762.1±180.1 | 5.56±0.48* | 0.94±0.016* |
| WF--P | 799.4±75.8# | 1022.5±80.8# | 6.5±0.29# | 0.97±0.007# |
| WM-C | 1219.5±36.7 | 1211.8±34.7 | 6.72±0.17 | 0.97±0.005 |
| WM-HFD | 1106.6±43.6 | 1108.9±46.4 | 6.12±0.44 | 0.94±0.027 |
| WM-P | 1207.6±34.9 | 1190.6±25.7 | 6.42±0.12 | 0.96±0.006 |
| AF-C | 956.8±72.8 | 944.6±65.1 | 6.05±0.35 | 0.95±0.02 |
| AF-HFD | 904.3±33.4 | 909.6±34.6 | 6.01±0.42 | 0.94±0.03 |
| AF-P | 472.4±51.7*# | 473.7±45.3*# | 4.29±0.39*# | 0.89±0.02*# |
| AM-C | 912.6±68.6 | 906.7±65.1 | 6.09±0.14 | 0.95±0.006 |
| AM-HFD | 958.7±47.3* | 947.2±39.2* | 6.38±0.17 | 0.97±0.004 |
| AM-P | 864.5±55.7# | 848.8±49.3# | 5.94±0.20# | 0.95±0.008 |
*p<0.05 compared with control group,#p<0.05 compared with fat group
Fig. 1, for not notable in the horizontal difference of door between the horizontal analysis result display each group of dams gut flora door, so
It is and horizontal in category：The relative amount calibration of Bacteroidetes S24-7, Allobaculum and Sutterella in fat group
Often group is obvious reduces, the intervention of compound probiotic mixture can increase Bacteroidetes S24-7, Allobaculum and
Sutterella relative amount.In addition fat group dams Lachnospiraceae, Bacteroides, Prevotella,
Mucispirillum, Helicobacter, Rikenellaceae and Ruminococcaceae content are higher than normal control
Group, the intervention of compound probiotic mixture can reduce the content of these bacterium.
1 is the results are shown in Table for what 21 days (weaning stage) of sub- mouse and 42 days (manhood) gut flora detected, sub- mouse female 21
Chao1 and Shannon indexes in α-diversity of its gut flora are less than normal group, the female temper mouse of compound probiotic intervention group
α-diversity be higher than fat mouse mouse.
The mouse bacterial diversity of table 1 is analyzed.M-C is control group dams, and M-HFD is fat group dams, and M-P is compound prebiotic
Bacterium intervention group dams.WF-C is Normal group female weaning stage sub- mouse, and WF-HFD is fat group female weaning stage sub- mouse, WF-P
For compound probiotic intervention group female weaning stage sub- mouse, WM-C is Normal group male weaning stage sub- mouse, and WM-HFD is obesity
The male weaning stage sub- mouse of group, WM-P is compound probiotic intervention group male weaning stage sub- mouse；AF-C be Normal group female into
Term sub- mouse, AF-HFD are fat group female adult phase sub- mouse, and AF-P is compound probiotic intervention group female adult phase sub- mouse,
AM-C is Normal group male adult phase sub- mouse, and AM-HFD is fat group male adult phase sub- mouse, and AM-P is compound probiotic
Intervention group male adult phase sub- mouse.
Fig. 2 shows that compared with the sub- mouse of Normal group, fat group is female for the horizontal analysis result of sub- mouse gut flora door
Temper mouse weaning stage Firmicutes rise Bacteroidetes reduce, the female temper mouse of compound probiotic intervention group door it is horizontal with normally it is right
It is not notable according to group difference.It is horizontal in category, compared with normal control female weaning stage sub- mouse, the female temper mouse weaning stage S24- of fat group
7, Prevotella, Rikenellaceae and Ruminococcaceae relative amounts reduce, Bacteroides and
Parabacteroides relative amount rise.Compound probiotic intervenes the enterobacteriaceae of the female temper mouse of compound probiotic intervention group
Group is not notable with normal group difference.The male 21 days gut floras of sub- mouse are shown in door horizontal analysis result：It is male with Normal group
Property compare, fat group male sub- mouse weaning stage Bacteroidetes rise, Firmicutes reduce.The sub- mouse of compound probiotic intervention group male
Weaning stage, is not notable with Normal group difference.Horizontal, the sub- mouse male weaning stage S24-7 of fat group in category,
Lachnospiraceae and Bacteroides relative amount is higher than control group, and Lactobacillus, Allobaculum,
Prevotella and Sutterella relative amount is less than control group.Compound probiotic intervention is advantageous to improve weaning stage male
The Flora Disturbance of sub- mouse.The female temper mouse analysis of intestinal microflora result of 42 days is shown, in horizontal fat group female adult phase of door
In generation, is not notable with normal group difference, and the Firmicutes of compound probiotic intervention group manhood Female offspring are higher than fat group
Generation.Horizontal in category, compared with fat group and Normal group, compound probiotic intervention group has higher level
Bacteroidaceae, Lachnospiraceae and Sutterella, the Lactobacillus of reduced levels,
Prevotella, Helicobacter, Rikenellaceae and Parabacteroides.42 days gut floras of male sub- mouse
As a result show：Horizontal in door, compared with control group, the sub- mouse manhood Firmicutes increase of fat group male, Bacteroidetes reduces.
It is horizontal in category, compared with Normal group, fat group male sub- mouse manhood Bacteroides, Helicobacter,
Ruminococcus and Mucispirillum contents raise, and S24-7 contents reduce.Compound probiotic intervenes part and reverses male
The Flora Disturbance of sub- mouse manhood.
The change of each group lipid of mice is shown in Table 2：
Table 2
*p<0.05 compared with control group,#p<0.05 compared with fat group
The lipid of mice of table 2 is analyzed.M-C is control group dams, and M-HFD is fat group dams, and M-P is compound probiotic intervention
Group dams.WF-C is Normal group female weaning stage sub- mouse, and WF-HFD is fat group female weaning stage sub- mouse, and WF-P is compound
Probiotics intervention group female weaning stage sub- mouse, WM-C are Normal group male weaning stage sub- mouse, and WM-HFD is fat group male
Weaning stage sub- mouse, WM-P are compound probiotic intervention group male weaning stage sub- mouse；AF-C is Normal group female adult phase
Mouse, AF-HFD are fat group female adult phase sub- mouse, and AF-P is compound probiotic intervention group female adult phase sub- mouse, and AM-C is just
Sub- mouse of normal control group male adult phase, AM-HFD are fat group male adult phase sub- mouse, and AM-P is that compound probiotic intervention group is male
Property manhood sub- mouse.TC is total cholesterol level, and TG is triglyceride content, and HDL is hdl concentration, and LDL is low
Density lipoprotein level.
The content rise of fat group dams serum total cholesterol, compound probiotic intervention can reduce high fat diet dams
Serum total cholesterol.The sub- mouse of fat group in the content of weaning stage and manhood serum total cholesterol apparently higher than control group, it is compound
Probiotics intervenes the content that can reduce high fat diet dams filial generation serum total cholesterol.
Claims (4)
1. a kind of be used to improve composite probiotics preparations that are fat and reducing blood fat, it is characterised in that：By following probiotics press than
Example mixes bifidobacterium breve (Bifidobacterium breve)：Lactobacillus acidophilus (Lactobacillus
acidophilus)：Lactobacillus casei (Lactobacillus casei)：Streptococcus thermophilus (Sterptococcus
Thermophilus active bacteria number ratio) is 0.5-1.5：0.5-1.5：0.5-1.5：0.5-1.5.
2. a kind of composite probiotics preparations for being used to improve obesity and reduce blood fat according to claim 1, its feature exist
In：The total number of viable of composite probiotics preparations is at least 2,000,000,000/mL.
3. the application of the composite probiotics preparations described in claim 1, it is characterised in that：The application is in the gestational period and lactation
Phase gives obese mother and takes composite probiotics preparations described in claim 1, to improve filial generation Flora Disturbance and blood lipid level.
4. the application of the composite probiotics preparations described in claim 1, it is characterised in that：The application is in the gestational period and lactation
Phase gives obese mother and takes composite probiotics preparations described in claim 1, its effect of flora and blood fat and improving to filial generation
It can continue until the manhood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711081761.4A CN107684567A (en) | 2017-11-07 | 2017-11-07 | It is a kind of to be used to improve composite probiotics preparations that are fat and reducing blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711081761.4A CN107684567A (en) | 2017-11-07 | 2017-11-07 | It is a kind of to be used to improve composite probiotics preparations that are fat and reducing blood fat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107684567A true CN107684567A (en) | 2018-02-13 |
Family
ID=61154746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711081761.4A Pending CN107684567A (en) | 2017-11-07 | 2017-11-07 | It is a kind of to be used to improve composite probiotics preparations that are fat and reducing blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107684567A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019189408A1 (en) * | 2018-03-29 | 2019-10-03 | 森永乳業株式会社 | Obesity treatment using probiotics, composition for reducing body fat, and composition for reducing waist circumference |
| TWI844535B (en) | 2018-03-29 | 2024-06-11 | 日商森永乳業股份有限公司 | Use of Bifidobacterium breve MCC1274, method for screening Bifidobacterium bacteria with anti-obesity effect, and method for screening responders to Bifidobacterium bacteria with anti-obesity effect |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104398538A (en) * | 2014-10-28 | 2015-03-11 | 大连医科大学 | Composite probiotics preparation for mitigating chemotherapy side effect |
| CN106389480A (en) * | 2016-08-24 | 2017-02-15 | 大连医科大学 | Complex probiotic preparation for reducing 5-hydroxytryptamine side effects after chemotherapy |
-
2017
- 2017-11-07 CN CN201711081761.4A patent/CN107684567A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104398538A (en) * | 2014-10-28 | 2015-03-11 | 大连医科大学 | Composite probiotics preparation for mitigating chemotherapy side effect |
| CN106389480A (en) * | 2016-08-24 | 2017-02-15 | 大连医科大学 | Complex probiotic preparation for reducing 5-hydroxytryptamine side effects after chemotherapy |
Non-Patent Citations (1)
| Title |
|---|
| PRADOS-BO A等: "Role of probiotics in obesity management", 《NUTR HOSP.》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019189408A1 (en) * | 2018-03-29 | 2019-10-03 | 森永乳業株式会社 | Obesity treatment using probiotics, composition for reducing body fat, and composition for reducing waist circumference |
| JPWO2019189408A1 (en) * | 2018-03-29 | 2021-03-18 | 森永乳業株式会社 | Treatment of obesity using probiotics, composition for reducing body fat, and composition for reducing waist circumference |
| JP7408539B2 (en) | 2018-03-29 | 2024-01-05 | 森永乳業株式会社 | Treatment of obesity using probiotics, composition for reducing body fat, and composition for reducing waist circumference |
| TWI844535B (en) | 2018-03-29 | 2024-06-11 | 日商森永乳業股份有限公司 | Use of Bifidobacterium breve MCC1274, method for screening Bifidobacterium bacteria with anti-obesity effect, and method for screening responders to Bifidobacterium bacteria with anti-obesity effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Role of dietary nutrients in the modulation of gut microbiota: a narrative review | |
| O'Neill et al. | Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases | |
| Mills et al. | Precision nutrition and the microbiome part II: potential opportunities and pathways to commercialisation | |
| Gomez-Gallego et al. | The human milk microbiome and factors influencing its composition and activity | |
| Vandenplas et al. | Prebiotics in infant formula | |
| EP3212208B1 (en) | Use of l. reuteri for prevention or treatment of microbiota dysbiosis in early life | |
| Hendaus et al. | Allergic diseases among children: nutritional prevention and intervention | |
| JP2020528401A (en) | Use of lactic acid bacteria to treat or prevent at least one of postpartum depression and postpartum anxiety | |
| JP4942831B2 (en) | Antiallergic composition | |
| Kondo et al. | Modulatory effects of Bifidobacterium longum BB536 on defecation in elderly patients receiving enteral feeding | |
| Quin et al. | Human behavior, not race or geography, is the strongest predictor of microbial succession in the gut bacteriome of infants | |
| AU2014350419A1 (en) | Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section | |
| CN106659226A (en) | Prebiotics for reducing the risk of obesity later in life | |
| Estorninos et al. | Term infant formula supplemented with milk-derived oligosaccharides shifts the gut microbiota closer to that of human milk-fed infants and improves intestinal immune defense: a randomized controlled trial | |
| CN107920579A (en) | The intestinal microbiota close with the intestinal microbiota of the infant of breast-feeding for induction includes bifidobacterium animalis acid subspecies（Bifidobacterium animalis ssp.lactis）And the alimentation composition and infant formula of the mixture of optional oligosaccharide | |
| Grüber | Probiotics and prebiotics in allergy prevention and treatment: future prospects | |
| Björkstén | Disease outcomes as a consequence of environmental influences on the development of the immune system | |
| Jielong et al. | Gut dysbiosis during early life: causes, health outcomes, and amelioration via dietary intervention | |
| AboNahas et al. | Trust your gut: the human gut microbiome in health and disease | |
| Park et al. | Comprehensive analysis of the effect of probiotic intake by the mother on human breast milk and infant fecal microbiota | |
| CN107684567A (en) | It is a kind of to be used to improve composite probiotics preparations that are fat and reducing blood fat | |
| Chawla et al. | Gut microbiome dysbiosis in malnutrition | |
| Zarezadeh et al. | Dietary pattern in autism increases the need for probiotic supplementation: A comprehensive narrative and systematic review on oxidative stress hypothesis | |
| Xie et al. | Supplementing maternal diet with milk oligosaccharides and probiotics helps develop the immune system and intestinal flora of offsprings | |
| Galyean et al. | Immunometabolism, Micronutrients, and Bariatric Surgery: The Use of Transcriptomics and Microbiota‐Targeted Therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20181127 Address after: 116000 West Section 9 of Lushun South Road, Lushunkou District, Dalian City, Liaoning Province Applicant after: Dalian Medical Univ. Applicant after: Biostime (Guangzhou) Health Products Co. Ltd. Address before: 116000 West Section 9 of Lushun South Road, Lushunkou District, Dalian City, Liaoning Province Applicant before: Dalian Medical Univ. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180213 |